Top Markets
Coin of the day
Annovis Bio, Inc. Annovis Bio, Inc.

Annovis Bio, Inc.

ANVS
Ранг среди акций #23205
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on... Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
Цена акции
$1.81
Последняя синхронизация: 2026-08-21
Рыночная капитализация
$77.00M
Изменение (1 день)
1.30%
Изменение (1 год)
-23.63%
Страна
US
Торговля Annovis Bio, Inc. (ANVS)

Категория

EPS для Annovis Bio, Inc. (ANVS)
EPS по состоянию на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций Annovis Bio, Inc., текущий EPS компании (TTM) составляет 0. В конце 2026 EPS компании составлял 0, равна показателю 2026 года, равному 0.
История EPS компании Annovis Bio, Inc. с 2026 по 2026
EPS на конец каждого года
Год EPS Изменить
Недостаточно данных для указанных дат.
EPS для аналогичных компаний или конкурентов
Компания EPS Разница в EPS Страна
$17.32 -
US
$27.74 -
NL
$-7.98 -
US
$-5.29 -
AU
- -
CH